Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
248 hedge funds and large institutions have $3.74B invested in Blueprint Medicines in 2022 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 85 increasing their positions, 91 reducing their positions, and 64 closing their positions.
59% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $7.29M
0.66% more ownership
Funds ownership: 100.38% → 101.04% (+0.66%)
7% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 91
11% less funds holding
Funds holding: 280 → 248 (-32)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
41% less capital invested
Capital invested by funds: $6.29B → $3.74B (-$2.55B)
47% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 64
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$214M |
| 2 |
CCM
Cadian Capital Management
New York
|
+$106M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$39.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$38.4M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TimesSquare Capital Management
New York
|
-$82.1M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$60.2M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$54.8M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$50.5M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
-$47.5M |
BPMC Hedge Fund Activity: Q1 2022 in Review
248 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2022, worth a combined $3.74B — down 41% from $6.29B a quarter earlier.
Sellers outnumbered buyers: 64 funds closed out of BPMC and 34 opened new positions — a net loss of 30 holders — while 91 trimmed existing stakes and 85 added.
The largest buyer was Fidelity Investments, adding an estimated $214M. The largest seller was TimesSquare Capital Management, cutting an estimated $82.1M.
- 248 institutional investors held Blueprint Medicines (BPMC) as of Q1 2022, down from 280 in Q4 2021.
- Funds reported $3.74B of Blueprint Medicines stock for Q1 2022, down 41% quarter-over-quarter.
- 34 funds opened new Blueprint Medicines positions in Q1 2022 and 64 closed out, a net change of -30 holders.
- The largest Blueprint Medicines buyer in Q1 2022 was Fidelity Investments, an estimated $214M added.
- The largest Blueprint Medicines seller in Q1 2022 was TimesSquare Capital Management, an estimated $82.1M sold.
Based on aggregated 13F filings for Q1 2022.